Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Tisotumab Vedotin in Solid Tumors
NCT03245736Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Aug 2017
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tisotumab vedotin in ovarian cancer, Cervical Cancer (CC), endometrial cancer (EC) and 5 more, sponsored by Seagen Inc. Primary endpoint: Treatment Emergent Adverse Events. Started Aug 2017; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
ovarian cancerCervical Cancer (CC)endometrial cancer (EC)bladder cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT03245736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245736.